Parmantier keeps Evonik stock at Hold in sector study

Published on 10/07/2026 at 09:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Parmantier set a EUR 20.50 target on October 6, 2026. Evonik stock was EUR 20.78 on October 6, 2026, plus 0.39 percent versus EUR 20.70.

Geometrisches Bauhaus-Poster mit fettem Text CHEMIE in Primärfarben Rot Gelb Blau nach 1920er Stil — Evonik Industries DE000EVNK013 als geometrisches Bauhaus-Poster mit dem Sektor-Text CHEMIE in leuchtenden Primärfarben, Illustration mit AI erstellt.

Parmantier & Cie. maintained a Hold rating on Evonik Industries AG with a EUR 20.50 six-month target in research dated October 6, 2026, according to EQS News. The report places Evonik stock at the intersection of stronger near-term earnings and unresolved structural pressure in European chemicals.

Hold rating meets takeover uncertainty

The research describes BASF's approach to Evonik as non-binding and exploratory rather than an agreed transaction, leaving the terms, financing, timetable and completion uncertain, EQS News reported in the same October 6 research release. That distinction matters because the investment case cannot yet treat a takeover price as a completed corporate outcome.

The same report assigns a EUR 20.50 target for six months, while the last Xetra price available for October 6 was EUR 20.78. The target therefore stood EUR 0.28, or 1.35 percent, below that price, making the Hold rating consistent with limited near-term valuation upside in the published assessment.

Second-quarter earnings support the case

Evonik's adjusted EBITDA reached EUR 630.0 million in the second quarter of 2026, a 24.00 percent increase from the comparable period. The figure and comparison were discussed in the company's Q2 earnings call transcript published by Yahoo Finance.

Management said first-half adjusted EBITDA reached EUR 1.1 billion and that the midpoint of the full-year outlook had increased by EUR 250.0 million. The call also highlighted a counterweight: Evonik expects normalization in selected businesses, while visibility remains subdued in several parts of the portfolio.

Results date gives the next test

Evonik's investor-relations calendar schedules its third-quarter 2026 report for November 3, 2026, according to the company's investor-relations page. That report will test whether the second-quarter earnings lift is broadening beyond temporary supply and pricing effects.

Evonik was last at EUR 20.78 on Xetra on October 6, 2026 at 5:35 p.m. CEST, plus 0.39 percent versus the Xetra close of EUR 20.70 on October 5, 2026. The 52-week Xetra range was EUR 12.49 to EUR 21.04 as of October 6, 2026, placing the price 1.24 percent below the high. Price source: substitute price Xetra, Lang & Schwarz without data set.